Nucleic acid delivery composition and carrier composition, pharmaceutical composition using the same, and method for nucleic acid delivery

Patent metadata

Field	Value
Publication number	US-9314529-B2
Application number	US-201113808237-A
Country	US
Kind code	B2
Filing date	Jul 11, 2011
Priority date	Jul 9, 2010
Publication date	Apr 19, 2016
Grant date	Apr 19, 2016

Abstract

An excellent nucleic acid delivery composition is provided which has reduced cytotoxicity and improved nucleic acid introduction efficiency and gene expression efficiency. The composition comprises: a block copolymer having an uncharged hydrophilic polymer segment and a cationic polymer segment; a cationic polymer; and a nucleic acid, wherein the mol percentage (B/H ratio) of the cationic groups of the block copolymer to the total cationic groups of the block copolymer and the cationic polymer is between 25% and 90%.

First claim

The invention claimed is:

1. A nucleic acid delivery composition for delivering a nucleic acid to a target cell or tissue, comprising: a block copolymer having an uncharged hydrophilic polymer segment and a cationic polymer segment; a second cationic polymer; and a nucleic acid,
wherein the uncharged hydrophilic polymer segment of the block copolymer is a polyalkylene glycol segment, the cationic polymer segment of the block copolymer is a segment made of poly(amino acid) having amino groups at its side chains, and the second cationic polymer is poly(amino acid) having amino groups at its side chains,
wherein the mol percentage (B/H ratio) of the cationic groups of the block copolymer to the total cationic groups of the block copolymer and the second cationic polymer is between 25% and 90%,
wherein said block copolymer is selected from the group consisting of formulae (I) to (IV):

wherein, in formulae (I) and (II),
R 1 represents a hydrogen atom or unsubstituted or substituted, linear or branched C 1-12 alkyl group,
R 2 represents a methylene group or ethylene group,
R 3 represents a hydrogen atom, protecting group, hydrophobic group or polymerizable group,
R 4 is either the same as R 5 or represents an initiator residue,
R 5 respectively and independently represent a hydroxyl group, oxybenzyl group or —NH—(CH 2 ) a —X group,
X respectively and independently represents a bulky amine compound residue having a pKa value of 7.4 or less, an amine compound residue containing one type or two or more types of a primary, secondary, tertiary or quaternary amine, or a non-amine compound residue,
L 1 and L 2 respectively and independently represent a linking group,
a represents an integer of 1 to 5,
m represents an integer of 5 to 20,000,
n represents an integer of 2 to 5,000, and
x represents an integer of 0 to 5,000, provided that x is not greater than n;

wherein, in formulae (III) and (IV),
R 1 represents a hydrogen atom or unsubstituted or substituted, linear or branched C 1-12 alkyl group,
R 2 represents a methylene group or ethylene group,
R 3 represents a hydrogen atom, protecting group, hydrophobic group or polymerizable group,
R 4 is either the same as R 5 or represents an initiator residue,
R 5 respectively and independently represent a hydroxyl group, oxybenzyl group or —NH—(CH 2 ) a —X group, provided that 85% or more of R 5 are —NH—(CH 2 ) a —X groups,
X respectively and independently represents a bulky amine compound residue having a pKa value of 7.4 or less, an amine compound residue containing one type or two or more types of a primary, secondary, tertiary or quaternary amine, or a non-amine compound residue,
L 1 and L 2 respectively and independently represent a linking group,
a represents an integer of 1 to 5,
R 6 respectively and independently represents a hydrogen atom or protecting group,
m represents an integer of 5 to 20,000,
n represents an integer of 2 to 5,000,
y represents an integer of 0 to 5,000 and
z represents an integer of 0 to 5,000, provided that y+z is not greater than n; and
wherein said second cationic polymer is selected from the group consisting of formulae (I′) to (IV′):

wherein, in formulae (I′) and (II′), R 2 , R 3 , R 4 , R 5 , n and x have the same meanings as defined in formulae (I) and (II);

wherein, in formulae (III′) and (IV′), R 2 , R 3 , R 4 , R 5 , R 6 , n, x, y and z have the same meanings as defined in formulae (III) and (IV).

2. The nucleic acid delivery composition according to claim 1 , wherein the mol ratio (N/P ratio) of the total cationic groups of the block copolymer and the cationic polymer to the phosphate groups of the nucleic acid is between 2 and 200.

3. The nucleic acid delivery composition according to claim 1 , which is in a particulate form.

4. A carrier composition for delivering a nucleic acid to a target cell or tissue, comprising: a block copolymer having an uncharged hydrophilic polymer segment and a cationic polymer segment; and a second cationic polymer,
wherein the uncharged hydrophilic polymer segment of the block copolymer is a polyalkylene glycol segment, the cationic polymer segment of the block copolymer is a segment made of poly(amino acid) having amino groups at its side chains, and the second cationic polymer is poly(amino acid) having amino groups at its side chains, and
wherein the mol percentage (B/H ratio) of the cationic groups of the block copolymer to the total cationic groups of the block copolymer and the second cationic polymer is between 25% and 90%,
wherein said block copolymer is selected from the group consisting of formulae (I) to (IV):

wherein, in formulae (I) and (II),
R 1 represents a hydrogen atom or unsubstituted or substituted, linear or branched C 1-12 alkyl group,
R 2 represents a methylene group or ethylene group,
R 3 represents a hydrogen atom, protecting group, hydrophobic group or polymerizable group,
R 4 is either the same as R 5 or represents an initiator residue,
R 5 respectively and independently represent a hydroxyl group, oxybenzyl group or —NH—(CH 2 ) a —X group, provided that 85% or more of R 5 are —NH—(CH 2 ) a —X groups,
X respectively and independently represents a bulky amine compound residue having a pKa value of 7.4 or less, an amine compound residue containing one type or two or more types of a primary, secondary, tertiary or quaternary amine, or a non-amine compound residue,
L 1 and L 2 respectively and independently represent a linking group,
a represents an integer of 1 to 5,
m represents an integer of 5 to 20,000,
n represents an integer of 2 to 5,000, and
x represents an integer of 0 to 5,000, provided that x is not greater than n;

wherein, in formulae (III) and (IV),
R 1 represents a hydrogen atom or unsubstituted or substituted, linear or branched C 1-12 alkyl group,
R 2 represents a methylene group or ethylene group,
R 3 represents a hydrogen atom, protecting group, hydrophobic group or polymerizable group,
R 4 is either the same as R 5 or represents an initiator residue,
R 5 respectively and independently represent a hydroxyl group, oxybenzyl group or —NH—(CH 2 ) a —X group, provided that 85% or more of R 5 are —NH—(CH 2 ) a —X groups,
X respectively and independently represents a bulky amine compound residue having a pKa value of 7.4 or less, an amine compound residue containing one type or two or more types of a primary, secondary, tertiary or quaternary amine, or a non-amine compound residue,
L 1 and L 2 respectively and independently represent a linking group,
a represents an integer of 1 to 5,
R 6 respectively and independently represents a hydrogen atom or protecting group,
m represents an integer of 5 to 20,000,
n represents an integer of 2 to 5,000,
y repr

Assignees

• Kataoka Kazunori
• Ishii Takehiko
• Osada Kensuke
• Chen Qixian
• Itaka Keiji
• Uchida Satoshi
• Univ Tokyo

Inventors

• Kataoka Kazunori
• Ishii Takehiko
• Osada Kensuke
• Chen Qixian
• Itaka Keiji
• Uchida Satoshi

Classifications

• C12N15/87 Primary

  Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title

• A61K47/34 Primary

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61K47/48853

  Human Necessities · mapped topic

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title